Baxter Healthcare Corporation has received final FDA approval to manufacture a generic drug designated by ANDA217072, a development anticipated to bolster the company’s revenue streams via market share gains. The designation signals a pivotal entry into the pharmaceutical sector, potentially altering the competitive landscape while driving growth in the generic drug market.